share_log

SVB Leerink Maintains Outperform on Vertex Pharmaceuticals, Lowers Price Target to $365

Benzinga Real-time News ·  Feb 8, 2023 17:55

SVB Leerink analyst David Risinger maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Outperform and lowers the price target from $374 to $365.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment